

WORKUP REQUEST

Patient name: (Last name, first name)	Hema-Quebec Patient ID:
Patient DOB : (dd/mm/yyyy)	International Patient ID:
Transplant Center (TC):	Hema-Quebec Donor ID:
Donor Registry :	International Donor ID:

SECTION 1 – PATIENT STATUS

Diagnosis :	Gender :	Weight: kg	ABO/Rh :	CMV : <input type="checkbox"/> Négative <input type="checkbox"/> Positive
Disease Status :				
Transplant History : <input type="checkbox"/> N/A <input type="checkbox"/> Autologous <input type="checkbox"/> Allogeneic related <input type="checkbox"/> Allogeneic unrelated				
Date, if applicable: _____				
Are there any specific procedures (i.e. splenectomy) that your patient will require prior to transplant?				
Comments:				

SECTION 2 – COLLECTION REQUEST

		1 st Choice	2 nd Choice
Product Type (PBSC, BM or DLI)			
Product(s) included in the protocol that may later be requested:			
Reason for product preference: Information to be shared with the donor			
Preferred Collection Date	Planned Infusion Date	Days of conditioning regimen: _____	Date donor clearance is needed: _____
1.			
2.			
3.			

WORKUP REQUEST

Patient name: (Last name, first name)	Hema-Quebec Patient ID:
Patient DOB : (dd/mm/yyyy)	International Patient ID:
Transplant Center (TC):	Hema-Quebec Donor ID:
Donor Registry :	International Donor ID:

SECTION 3 – VERIFICATION HLA TYPING

Patient	Donor
<input type="checkbox"/> Results attached <input type="checkbox"/> Results pending (will be provided prior to donor clearance)	<input type="checkbox"/> Results attached <input type="checkbox"/> Results pending VT/Workup (will be provided prior to donor clearance)

SECTION 4 – PRE-COLLECTION SAMPLES (DONOR PERIPHERAL BLOOD max 50 mL)

Clotted (no anti-coagulant)	mL	Sample to be shipped to : please print clearly	
ACD-A	mL		Name: _____
Sodium Heparin	mL		Address: _____
EDTA	mL		_____
Other:	mL		Phone/Fax: _____
Samples delivery (days accepted): <input type="checkbox"/> Special storage, handling and transportation instructions, attached.		<input type="checkbox"/> Monday <input type="checkbox"/> Tuesday <input type="checkbox"/> Wednesday <input type="checkbox"/> Thursday <input type="checkbox"/> Friday <input type="checkbox"/> Saturday <input type="checkbox"/> Sunday	

WORKUP REQUEST

Patient name: (Last name, first name)	Hema-Quebec Patient ID:
Patient DOB : (dd/mm/yyyy)	International Patient ID:
Transplant Center (TC):	Hema-Quebec Donor ID:
Donor Registry :	International Donor ID:

SECTION 5 – COLLECTION PRESCRIPTIONS AND SPECIFICATIONS FOR STEM CELL

	HPC, Marrow	HPC, Apheresis	MNC, Apheresis
Requested nucleated cell per kg (uncorrected)	$\times 10^8$ TNC/kg	$\times 10^6$ CD34 ⁺ /kg	$\times 10^8$ CD3 ⁺ /kg
X Recipient weight (kg)	kg	kg	kg
= Total nucleated cells for recipient (uncorrected)	$\times 10^8$	$\times 10^6$	$\times 10^8$
+ Nucleated Cells for Quality control	$\times 10^8$	$\times 10^6$	$\times 10^8$
= Total nucleated cells requested	$\times 10^8$ TNC	$\times 10^6$ CD34⁺	$\times 10^8$ CD3⁺
If additional plasma required, specify final concentration			
Requested storage temperature:	°C	°C	°C
Estimated minimum marrow volume base on the requested total nucleated cell count (The maximum volume removed should not exceed 20 ml/kg donor weight)			
Bone Marrow	Heparin: μ /ml	ACD-A: vol. ACD-A:vol.BM	
Required anticoagulant	<input type="checkbox"/> According to CC collection procedure	Other, please describe:	
Bone marrow manipulation prior to infusion Yes <input type="checkbox"/> No <input type="checkbox"/>	<input type="checkbox"/> Red cell depletion <input type="checkbox"/> Plasma reduction	Other, please describe :	

WORKUP REQUEST

Patient name: (Last name, first name)	Hema-Quebec Patient ID:
Patient DOB : (dd/mm/yyyy)	International Patient ID:
Transplant Center (TC):	Hema-Quebec Donor ID:
Donor Registry :	International Donor ID:

SECTION 6 – SAMPLES TO BE PROVIDED AT TIME OF COLLECTION

Peripheral Blood Samples from Donor (max 50 mL)		Product Samples	
Clotted (no anti-coagulant)	mL	Clotted (no anti-coagulant)	mL
ACD-A	mL	ACD-A	mL
Sodium Heparin	mL	Sodium Heparin	mL
EDTA	mL	EDTA	mL
Other, specify:	mL	Other, specify:	mL

SECTION 7 – RESEARCH

Will stem cell product or blood samples be used for research? Yes (complete below) No

Research protocol name	
TC research protocol ID	
Approved by local IRB?	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A
Please provide a copy of the research protocol and donor consent form	<input type="checkbox"/> Attached <input type="checkbox"/> Previously provided to Hema-Quebec

I verify that the ABO type, degree of HLA match and infectious disease marker results are acceptable to proceed with stem cell collection for above patient.

Completed by: _____ Date: _____
dd/mm/yyyy

On behalf of Ordering Physician: _____
(Please print clearly)

WORKUP REQUEST

Patient name: (Last name, first name)	Hema-Quebec Patient ID:
Patient DOB : (dd/mm/yyyy)	International Patient ID:
Transplant Center (TC):	Hema-Quebec Donor ID:
Donor Registry :	International Donor ID:

SECTION 8 – PRODUCT DELIVERY INFORMATION

Transplant center Name	
Contact person	
Address (#, street, city, province, postal code, country)	
Telephone No.	
Pager No.	

NOTE FOR THE COLLECTION CENTER:

- Transplant centers (TCs) are responsible to ensure proper product transportation according to applicable FACT and Canadian regulations.
- All TCs within the province of Quebec in Canada are FACT accredited and provide validated transport boxes which meet FACT, WMDA and Health Canada regulations.
- TCs may request early product release or overnight product storage according to what they consider appropriate in order to deliver the product under the proper conditions and as quickly as possible.
- Collection centers (CCs) will not be held responsible for loss of product viability if TC fails to provide proper transport conditions.

DISCLAIMER

- The cell products collected from this donor are intended solely for the purpose of immediate therapeutic treatment for the above mentioned patient. Any planned cryopreservation of the cell products prior to initial infusion to the patient may only occur with the advance written approval from the donor.
- Excess cells may be cryopreserved and stored for future therapeutic treatment of the above mentioned patient. No other uses of these cells are permissible. Cells not used for the therapeutic treatment of the above mentioned patient must be properly discarded and details must be provided to the CC.
- The donor center must be provided detailed information concerning the use and/or disposal of all portions of this cryopreserved cell product. By accepting these cells, the transplant physician also accepts these terms and conditions. Deviations from these terms are not permitted without prior written approval from the Registry.
- Any serious product event and/or adverse reactions must be reported both to the donor's registry and transplant center. Corresponding SEAR/SPEAR reports must be completed by the registry providing the product, submitted to the WMDA office and details must be provided to the CC.